Cell Reports (Aug 2021)
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
- Daniel Lozano-Ojalvo,
- Carmen Camara,
- Eduardo Lopez-Granados,
- Pilar Nozal,
- Lucía del Pino-Molina,
- Luz Yadira Bravo-Gallego,
- Estela Paz-Artal,
- Marjorie Pion,
- Rafael Correa-Rocha,
- Alberto Ortiz,
- Marcos Lopez-Hoyos,
- Marta Erro Iribarren,
- Jose Portoles,
- Maria Pilar Rojo-Portoles,
- Gloria Ojeda,
- Isabel Cervera,
- Maria Gonzalez-Perez,
- Irene Bodega-Mayor,
- Maria Montes-Casado,
- Pilar Portoles,
- Mayte Perez-Olmeda,
- Jesus Oteo,
- Rodrigo Sanchez-Tarjuelo,
- Venu Pothula,
- Megan Schwarz,
- Manisha Brahmachary,
- Anthony Tanoto Tan,
- Nina Le Bert,
- Cecilia Berin,
- Antonio Bertoletti,
- Ernesto Guccione,
- Jordi Ochando
Affiliations
- Daniel Lozano-Ojalvo
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Carmen Camara
- Department of Immunology, Hospital La Paz, 28046 Madrid, Spain
- Eduardo Lopez-Granados
- Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain
- Pilar Nozal
- Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain; Complement Research Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain
- Lucía del Pino-Molina
- Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain
- Luz Yadira Bravo-Gallego
- Department of Immunology, Hospital La Paz, 28046 Madrid, Spain; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute of Biomedical Research (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER U767), 28046 Madrid, Spain
- Estela Paz-Artal
- Department of Immunology, Hospital 12 de Octubre, 28041 Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
- Marjorie Pion
- Laboratory of Immune-Regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28009 Madrid, Spain
- Rafael Correa-Rocha
- Laboratory of Immune-Regulation, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28009 Madrid, Spain
- Alberto Ortiz
- Department of Nephrology, IIS-Fundación Jimenez Díaz, 28040 Madrid, Spain
- Marcos Lopez-Hoyos
- Department of Immunology, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain
- Marta Erro Iribarren
- Department of Pneumology, Hospital Puerta de Hierro, 28220 Madrid, Spain
- Jose Portoles
- Department of Nephrology, Hospital Puerta de Hierro, 28220 Madrid, Spain
- Maria Pilar Rojo-Portoles
- Centro de Salud, Esquivias, 45221 Toledo, Spain
- Gloria Ojeda
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Isabel Cervera
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Maria Gonzalez-Perez
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Irene Bodega-Mayor
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Maria Montes-Casado
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Pilar Portoles
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain; Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain
- Mayte Perez-Olmeda
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Jesus Oteo
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Rodrigo Sanchez-Tarjuelo
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Venu Pothula
- Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain
- Megan Schwarz
- Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain
- Manisha Brahmachary
- Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain
- Anthony Tanoto Tan
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169547, Singapore
- Nina Le Bert
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169547, Singapore
- Cecilia Berin
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Antonio Bertoletti
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169547, Singapore
- Ernesto Guccione
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Corresponding author
- Jordi Ochando
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Corresponding author
- Journal volume & issue
-
Vol. 36,
no. 8
p. 109570
Abstract
Summary: The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
